Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Muñoz Torrico M, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ, Cirillo DM, Alagna R, Rendon A, Pontali E, Piubello A, Figueroa J, Ferlazzo G, García-Basteiro A, Centis R, Visca D, D'Ambrosio L, Sotgiu G; members of the Global Tuberculosis Network.

Int J Infect Dis. 2020 Feb 4. pii: S1201-9712(20)30045-X. doi: 10.1016/j.ijid.2020.01.042. [Epub ahead of print]

2.

Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases.

Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E.

Int J Infect Dis. 2019 Dec 27;92:62-68. doi: 10.1016/j.ijid.2019.12.031. [Epub ahead of print]

3.

Long-term safety and efficacy of dolutegravir and unboosted atazanavir among experienced HIV-infected adults.

Del Puente F, Pontali E, Torresin A, Cassola G.

AIDS. 2019 Dec 1;33(15):2446-2447. doi: 10.1097/QAD.0000000000002365. No abstract available.

PMID:
31764113
4.

TB consilia and quality of tuberculosis management.

Pontali E, Tadolini M, Migliori GB.

Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1048-1049. doi: 10.5588/ijtld.19.0423. No abstract available.

PMID:
31627767
5.

The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.

Caminero JA, García-Basteiro AL, Rendon A, Piubello A, Pontali E, Migliori GB.

Eur Respir J. 2019 Oct 10;54(4). pii: 1901272. doi: 10.1183/13993003.01272-2019. Print 2019 Oct. No abstract available.

PMID:
31601719
6.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Dec 19;54(6). pii: 1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec.

PMID:
31601711
7.

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives.

Pontali E, Raviglione MC, Migliori GB; and the writing group members of the Global TB Network Clinical Trials Committee.

Eur Respir Rev. 2019 May 29;28(152). pii: 190035. doi: 10.1183/16000617.0035-2019. Print 2019 Jun 30. Review.

8.

Recent evidence on delamanid use for rifampicin-resistant tuberculosis.

Pontali E, Centis R, D'Ambrosio L, Toscanini F, Migliori GB.

J Thorac Dis. 2019 Mar;11(Suppl 3):S457-S460. doi: 10.21037/jtd.2018.11.26. No abstract available.

9.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

10.

Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study.

Sane Schepisi M, Navarra A, Altet Gomez MN, Dudnyk A, Dyrhol-Riise AM, Esteban J, Giorgetti PF, Gualano G, Guglielmetti L, Heyckendorf J, Kaluzhenina A, Lange B, Lange C, Manika K, Miah J, Nanovic Z, Pontali E, Prego MR, Solovic I, Tiberi S, Palmieri F, Girardi E.

Open Forum Infect Dis. 2018 Dec 19;6(1):ofy337. doi: 10.1093/ofid/ofy337. eCollection 2019 Jan.

11.

Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.

Tiberi S, Pontali E, Tadolini M, D'Ambrosio L, Migliori GB.

Int J Infect Dis. 2019 Mar;80S:S68-S72. doi: 10.1016/j.ijid.2019.01.040. Epub 2019 Jan 25.

12.

Erysipelothrix rhusiopathiae septicaemia in systemic lupus erythematosus.

Feasi M, Pontali E, Usiglio D, Mori M, Cassola G.

Infez Med. 2018 Dec 1;26(4):356-358.

13.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7.

PMID:
30096332
14.

Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy.

Pontali E, Fiore V, Ialungo AM, Ranieri R, Mollaretti O, Barbarini G, Marri D, Prestileo T, Dell'Isola S, Rastrelli E, Leo G, Starnini G, Babudieri S, Madeddu G; Gruppo Infettivologi Penitenziari.

Int J Drug Policy. 2018 Sep;59:50-53. doi: 10.1016/j.drugpo.2018.06.017. Epub 2018 Jul 6.

PMID:
29986272
15.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

16.

Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.

Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.

Curr Opin Pulm Med. 2018 May;24(3):244-252. doi: 10.1097/MCP.0000000000000477. Review.

PMID:
29470252
17.

Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing.

Riccardi N, Giannini B, Borghesi ML, Taramasso L, Cattaneo E, Cenderello G, Toscanini F, Giacomini M, Pontali E, Cassola G, Viscoli C, Di Biagio A.

ERJ Open Res. 2018 Feb 2;4(1). pii: 00108-2017. doi: 10.1183/23120541.00108-2017. eCollection 2018 Jan.

18.

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.

Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701462. doi: 10.1183/13993003.01462-2017. Print 2017 Nov. No abstract available.

19.

Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.

Marras F, Casabianca A, Bozzano F, Ascierto ML, Orlandi C, Di Biagio A, Pontali E, Dentone C, Orofino G, Nicolini L, Taramasso L, Magnani M, Marincola FM, Wang E, Moretta L, De Maria A.

J Virol. 2017 Nov 14;91(23). pii: e00647-17. doi: 10.1128/JVI.00647-17. Print 2017 Dec 1.

20.

Post-implementation blues: the unfulfilled potential of Xpert.

Tiberi S, Pontali E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1073. doi: 10.5588/ijtld.17.0478. No abstract available.

PMID:
28911347
21.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

22.

Hospital admissions for HIV-infected prisoners in Italy.

Pontali E, Ranieri R, Rastrelli E, Iannece MD, Ialungo AM, Dell'Isola S, Liberti A, Rosario P, Casati R, Starnini G, Babudieri S.

Int J Prison Health. 2017 Jun 12;13(2):105-112. doi: 10.1108/IJPH-02-2016-0004.

PMID:
28581372
23.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

24.

Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.

Pontali E, D'Ambrosio L, Centis R, Sotgiu G, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1700146. doi: 10.1183/13993003.00146-2017. Print 2017 Mar. No abstract available.

25.

The cursed duet today: Tuberculosis and HIV-coinfection.

Tiberi S, Carvalho AC, Sulis G, Vaghela D, Rendon A, Mello FC, Rahman A, Matin N, Zumla A, Pontali E.

Presse Med. 2017 Mar;46(2 Pt 2):e23-e39. doi: 10.1016/j.lpm.2017.01.017. Epub 2017 Feb 28. Review.

PMID:
28256380
26.

Erratum to: Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel.

Ranieri R, Starnini G, Carbonara S, Pontali E, Leo G, Romano A, Panese S, Monarca R, Prestileo T, Barbarini G, Babudieri S; SIMSPe Group.

Infection. 2017 Apr;45(2):249. doi: 10.1007/s15010-017-0983-6. No abstract available.

PMID:
28181203
27.

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.

Int J Mol Sci. 2017 Feb 7;18(2). pii: E341. doi: 10.3390/ijms18020341. Review.

28.

Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel.

Ranieri R, Starnini G, Carbonara S, Pontali E, Leo G, Romano A, Panese S, Monarca R, Prestileo T, Barbarini G, Babudieri S; SIMSPe Group.

Infection. 2017 Apr;45(2):131-138. doi: 10.1007/s15010-016-0973-0. Epub 2016 Dec 26. Review. Erratum in: Infection. 2017 Apr;45(2):249.

PMID:
28025726
29.

Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study.

Sanarico N, D'Amato S, Bruni R, Rovetto C, Salvi E, Di Zeo P, Chionne P, Madonna E, Pisani G, Costantino A, Equestre M, Tosti ME, Cenci A, Maggiorella MT, Sernicola L, Pontali E, Pansera A, Quattrocchi R, Carbonara S, Signorile F, Surace LA, Federzoni G, Garlassi E, Starnini G, Monarca R, Babudieri S, Rapicetta M, Pompa MG, Caraglia A, Ensoli B, Ciccaglione AR, Buttò S.

Medicine (Baltimore). 2016 Nov;95(44):e5257.

30.

Recent developments in the diagnosis and management of tuberculosis.

Sulis G, Centis R, Sotgiu G, D'Ambrosio L, Pontali E, Spanevello A, Matteelli A, Zumla A, Migliori GB.

NPJ Prim Care Respir Med. 2016 Nov 3;26:16078. doi: 10.1038/npjpcrm.2016.78. Review.

31.

New anti-tuberculosis drugs for special populations: a difficult-to-address issue.

Sotgiu G, Pontali E, Centis R, D'Ambrosio L, Migliori GB.

Eur Respir J. 2016 Sep;48(3):957-8. doi: 10.1183/13993003.01289-2016. No abstract available.

32.

Unusual Presentation of Human Immunodeficiency Virus-Related Kaposi's Sarcoma.

Montinari MM, Anselmi L, Cozzi S, Bobbio N, Cechini M, Pontali E.

AIDS Res Hum Retroviruses. 2016 Dec;32(12):1169-1170. Epub 2016 Jun 21. No abstract available.

PMID:
27327416
33.

WHO strategies for the programmatic management of drug-resistant tuberculosis.

Matteelli A, Centis R, D'Ambrosio L, Sotgiu G, Tadolini M, Pontali E, Spanevello A, Migliori GB.

Expert Rev Respir Med. 2016 Sep;10(9):991-1002. doi: 10.1080/17476348.2016.1199278. Epub 2016 Jun 22. Review.

PMID:
27276361
34.

Blood-borne viral co-infections among human immunodeficiency virus-infected inmates.

Pontali E, Bobbio N, Zaccardi M, Urciuoli R.

Int J Prison Health. 2016 Jun 13;12(2):88-97. doi: 10.1108/IJPH-07-2015-0022.

PMID:
27219906
35.

Advancing global programmatic management of latent tuberculosis infection for at risk populations.

Getahun H, Matteelli A, Abubakar I, Hauer B, Pontali E, Migliori GB.

Eur Respir J. 2016 May;47(5):1327-30. doi: 10.1183/13993003.00449-2016. No abstract available.

36.

Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.

Pontali E, Sotgiu G, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2016 Feb;47(2):394-402. doi: 10.1183/13993003.01891-2015. No abstract available.

37.

Monitoring predictors of mortality: A necessary action to reach TB elimination.

Pontali E, Centis R, D'Ambrosio L, Migliori GB.

Rev Port Pneumol (2006). 2015 Nov 13. pii: S2173-5115(15)00187-6. doi: 10.1016/j.rppnen.2015.10.007. [Epub ahead of print] No abstract available.

PMID:
26590095
38.

Management of drug resistantTB in patients with HIV co-infection.

Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.

Expert Opin Pharmacother. 2015;16(18):2737-50. doi: 10.1517/14656566.2015.1100169. Epub 2015 Oct 19. Review.

PMID:
26478945
39.

New anti-tuberculosis drugs and regimens: 2015 update.

D'Ambrosio L, Centis R, Sotgiu G, Pontali E, Spanevello A, Migliori GB.

ERJ Open Res. 2015 May 6;1(1). pii: 00010-2015. eCollection 2015 May. Review.

40.

Multidrug-resistant tuberculosis in Europe, 2010-2011.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Pontali E, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; TBNET.

Emerg Infect Dis. 2015 Mar;21(3):409-16. doi: 10.3201/eid2103.141343.

41.

Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.

Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.

J Womens Health (Larchmt). 2015 Feb;24(2):159-64. doi: 10.1089/jwh.2014.4796. Epub 2015 Feb 3.

PMID:
25682817
42.

Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.

Sotgiu G, Pontali E, Centis R, D'Ambrosio L, Migliori GB.

Expert Rev Anti Infect Ther. 2015 Mar;13(3):305-15. doi: 10.1586/14787210.2015.1011127. Epub 2015 Feb 3. Review.

PMID:
25645397
43.

Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.

Sotgiu G, Pontali E, Migliori GB.

Eur Respir J. 2015 Jan;45(1):25-9. doi: 10.1183/09031936.00145014. Review. No abstract available.

44.

A new paradigm for multidrug-resistant tuberculosis?

Reichman LB, Schaaf HS, Pontali E, Migliori GB.

Int J Tuberc Lung Dis. 2014 Aug;18(8):884. doi: 10.5588/ijtld.14.0347. No abstract available.

PMID:
25198999
45.

Unusual presentation of visceral leishmaniasis in an HIV-infected patient.

Cenderello G, Pontali E, Ruggeri C, Dusi A, De Maria A.

AIDS Res Hum Retroviruses. 2014 Sep;30(9):846-7. doi: 10.1089/AID.2014.0118. Epub 2014 Aug 20. No abstract available.

PMID:
25054214
46.

Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.

Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M.

Antivir Ther. 2015;20(1):39-48. doi: 10.3851/IMP2781. Epub 2014 May 15.

PMID:
24831457
47.

OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.

Carosi G, Bruno R, Cariti G, Nasta P, Gulminetti R, Galli M, Angarano G, Verucchi G, Pontali E, Capetti A, Raise E, Ravasio V, Maida I, Iannacone C, Caputo A, Puoti M.

Antivir Ther. 2014;19(8):735-45. doi: 10.3851/IMP2757. Epub 2014 Feb 28.

PMID:
24583976
48.

An unexpected Streptococcus pneumoniae strain.

Cenderello G, Pontali E, Torresin A, Milano G, Ansaldi F, Feasi M, Usiglio D, Mori M, Icardi G, Cassola G.

J Chemother. 2014 Jun;26(3):173-5. doi: 10.1179/1973947813Y.0000000125. Epub 2013 Dec 6.

PMID:
24090710
49.

Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

Marras F, Nicco E, Bozzano F, Di Biagio A, Dentone C, Pontali E, Boni S, Setti M, Orofino G, Mantia E, Bartolacci V, Bisio F, Riva A, Biassoni R, Moretta L, De Maria A.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11970-5. doi: 10.1073/pnas.1302090110. Epub 2013 Jul 1.

50.

Drug-resistant tuberculosis.

Pontali E, Matteelli A, Migliori GB.

Curr Opin Pulm Med. 2013 May;19(3):266-72. doi: 10.1097/MCP.0b013e32835f1bf3. Review.

PMID:
23422415

Supplemental Content

Loading ...
Support Center